Latest Commercial Rollouts News

Skin Elements Limited advances its natural biotechnology products with ECO-Nurture trials concluding and SuprCuvr disinfectant gaining traction, supported by a successful $656k capital raise.

HITIQ Limited is pivoting towards grassroots athletes with its upcoming PROTEQT concussion management system, backed by strategic partnerships and fresh funding. The company aims for a cashflow positive future as it prepares for commercial rollout.

IMEXHS Limited reported modest revenue growth and a 16% increase in ARR in Q1 FY25, alongside the commercial rollout of its Aquila+ radiology platform and a $2.5 million capital raising to fuel expansion.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

Opyl Limited reports strong progress in AI-driven clinical trial optimisation with active commercial initiatives, strategic partnerships, and a planned capital raise to support growth amid tight cash reserves.

SportsHero Limited has made significant strides in commercialising its iGV Family Game Pass, securing key partnerships with major Southeast Asian telecom operators and expanding its market footprint to the Philippines.

Eden Innovations has landed a significant second order from Holcim Ecuador for its EdenCrete® Pz7 concrete additive, underscoring growing global interest in its low-carbon concrete solutions.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

BlinkLab has secured North Shore Pediatric Therapy as the second US clinical site in its autism diagnostic study, enhancing recruitment and data quality with a leading Chicago-based specialist.

PARKD has inked a pivotal five-year exclusive licensing agreement with Fielders, a BlueScope Steel division, to commercialise its innovative MDSB® and MDSS® products in Australia and explore international expansion.

Wellnex Life has secured Therapeutic Goods Administration approval for its Liquid Paracetamol plus Caffeine Soft Gel, marking its fourth market authorisation and opening new revenue avenues.